Regions Financial Corp Ligand Pharmaceuticals Inc Transaction History

Regions Financial Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 19, 2019	SELL	$107.38 - $129.34 $16,214 - $19,530	-151 Closed	0 $0
Q1 2019 Apr 19, 2019	SELL	$105.93 - $142.47 $244,698 - $329,105	-2,310 Reduced 93.86%	151 $19,000
Q4 2018 Jan 28, 2019	BUY	$128.36 - $272.13 $62,254 - $131,983	485 Added 24.54%	2,461 $334,000
Q3 2018 Oct 22, 2018	SELL	$211.18 - $274.49 $174,434 - $226,728	-826 Reduced 29.48%	1,976 $543,000
Q2 2018 Jul 26, 2018	SELL	$150.77 - $207.98 $53,523 - $73,832	-355 Reduced 11.24%	2,802 $581,000
Q1 2018 Apr 18, 2018	SELL	$138.63 - $182.62 $27,864 - $36,706	-201 Reduced 5.99%	3,157 $522,000
Q4 2017 Jan 18, 2018	SELL	$128.36 - $147.04 $49,161 - $56,316	-383 Reduced 10.24%	3,358 $459,000
Q3 2017 Oct 23, 2017	BUY	$120.91 - $137.94 $452,324 - $516,033	3,741	3,741 $509,000

248

17.6M

61K

7.8K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.91B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Regions Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Regions Financial Corp with notifications on news.